Author
Listed:
- Elodie Bal
(Columbia University)
- Rahul Kumar
(Columbia University
Indian Institute of Technology Hyderabad)
- Mohammad Hadigol
(Rutgers University)
- Antony B. Holmes
(Columbia University)
- Laura K. Hilton
(BC Cancer Research Centre)
- Jui Wan Loh
(Rutgers University)
- Kostiantyn Dreval
(Simon Fraser University)
- Jasper C. H. Wong
(BC Cancer Research Centre)
- Sofija Vlasevska
(Columbia University)
- Clarissa Corinaldesi
(Columbia University)
- Rajesh Kumar Soni
(Columbia University
Columbia University)
- Katia Basso
(Columbia University
Columbia University)
- Ryan D. Morin
(Simon Fraser University
BC Cancer Research Institute)
- Hossein Khiabanian
(Rutgers University
Rutgers University)
- Laura Pasqualucci
(Columbia University
Columbia University
Columbia University)
- Riccardo Dalla-Favera
(Columbia University
Columbia University
Columbia University
Columbia University)
Abstract
Diffuse large B cell lymphoma (DLBCL) is the most common B cell non-Hodgkin lymphoma and remains incurable in around 40% of patients. Efforts to sequence the coding genome identified several genes and pathways that are altered in this disease, including potential therapeutic targets1–5. However, the non-coding genome of DLBCL remains largely unexplored. Here we show that active super-enhancers are highly and specifically hypermutated in 92% of samples from individuals with DLBCL, display signatures of activation-induced cytidine deaminase activity, and are linked to genes that encode B cell developmental regulators and oncogenes. As evidence of oncogenic relevance, we show that the hypermutated super-enhancers linked to the BCL6, BCL2 and CXCR4 proto-oncogenes prevent the binding and transcriptional downregulation of the corresponding target gene by transcriptional repressors, including BLIMP1 (targeting BCL6) and the steroid receptor NR3C1 (targeting BCL2 and CXCR4). Genetic correction of selected mutations restored repressor DNA binding, downregulated target gene expression and led to the counter-selection of cells containing corrected alleles, indicating an oncogenic dependency on the super-enhancer mutations. This pervasive super-enhancer mutational mechanism reveals a major set of genetic lesions deregulating gene expression, which expands the involvement of known oncogenes in DLBCL pathogenesis and identifies new deregulated gene targets of therapeutic relevance.
Suggested Citation
Elodie Bal & Rahul Kumar & Mohammad Hadigol & Antony B. Holmes & Laura K. Hilton & Jui Wan Loh & Kostiantyn Dreval & Jasper C. H. Wong & Sofija Vlasevska & Clarissa Corinaldesi & Rajesh Kumar Soni & K, 2022.
"Super-enhancer hypermutation alters oncogene expression in B cell lymphoma,"
Nature, Nature, vol. 607(7920), pages 808-815, July.
Handle:
RePEc:nat:nature:v:607:y:2022:i:7920:d:10.1038_s41586-022-04906-8
DOI: 10.1038/s41586-022-04906-8
Download full text from publisher
As the access to this document is restricted, you may want to search for a different version of it.
Citations
Citations are extracted by the
CitEc Project, subscribe to its
RSS feed for this item.
Cited by:
- Chuanjiang Yu & Qiong Shen & Antony B. Holmes & Tongwei Mo & Anna Tosato & Rajesh Kumar Soni & Clarissa Corinaldesi & Sanjay Koul & Laura Pasqualucci & Shafinaz Hussein & Farhad Forouhar & Riccardo Da, 2024.
"MEF2B C-terminal mutations enhance transcriptional activity and stability to drive B cell lymphomagenesis,"
Nature Communications, Nature, vol. 15(1), pages 1-19, December.
- Sebastian Carrasco Pro & Heather Hook & David Bray & Daniel Berenzy & Devlin Moyer & Meimei Yin & Adam Thomas Labadorf & Ryan Tewhey & Trevor Siggers & Juan Ignacio Fuxman Bass, 2023.
"Widespread perturbation of ETS factor binding sites in cancer,"
Nature Communications, Nature, vol. 14(1), pages 1-15, December.
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:nature:v:607:y:2022:i:7920:d:10.1038_s41586-022-04906-8. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.